Bill > LB512

This bill adopts the Chemical Abortion Safety Protocol Act, which establishes detailed requirements for physicians providing abortion-inducing drugs. The bill defines key terms like "abortion-inducing drug" and "adverse event," and mandates that before prescribing such drugs, physicians must conduct an in-person examination, verify pregnancy, check for ectopic pregnancy, document gestational age, determine the woman's blood type, and offer Rh immunoglobulin treatment if needed. Physicians must also schedule a follow-up visit between 3-14 days after providing the drug to confirm pregnancy termination and assess for any adverse events. Additionally, physicians are required to file a detailed report with the Department of Health and Human Services within 30 days, including information about the drug, follow-up visit, and any medical complications, while ensuring no personally identifying information is included. The bill also amends existing professional conduct rules to consider violation of this protocol as unprofessional conduct, and explicitly states that the woman herself cannot be held liable for violations of the act. The legislation aims to enhance medical oversight and safety protocols for chemical abortion procedures.